Loading...
XOSL
AKBM
Market cap763mUSD
Oct 27, Last price  
87.00NOK
1D
-1.02%
1Q
13.28%
IPO
-13.00%
Name

Aker Biomarine ASA

Chart & Performance

D1W1MN
P/E
4.24
P/S
3.84
EPS
2.06
Div Yield, %
51.72%
Shrs. gr., 5y
4.89%
Rev. gr., 5y
-4.17%
Revenues
199m
-40.65%
74,053,65612,189,59525,021,78652,050,55355,287,49484,002,607108,993,261112,299,000105,121,000116,737,000125,540,000154,182,000246,170,000288,588,000262,062,000277,200,000335,300,000199,000,000
Net income
180m
P
00028,916,9740046,593,795-17,258,000805,000-2,055,000-17,768,000-1,022,000-23,750,000-5,463,000-8,008,00010,000,000-9,000,000180,300,000
CFO
12m
-74.26%
00002,513,0675,373,3010-11,134,00018,269,00020,880,00007,894,00012,307,000-51,043,000729,00015,100,00047,400,00012,200,000
Dividend
Sep 09, 202445 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.
IPO date
Jul 06, 2020
Employees
626
Domiciled in
NO
Incorporated in
NO

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT